Low Intestinal IL22 Associates With Increased Transplant-Related Mortality After Allogeneic Stem Cell Transplantation

Sakhila Ghimire1*, Katharina U. Ederer2, Elisabeth Meedt1, Daniela Weber1, Carina Matos1, Andreas Hiergeist2, Florian Zeman3, Daniel Wolff1, Matthias Edinger1,4, Hendrik Poeck1,4, Wolfgang Herr1, André Gessner2, Ernst Holler1 and Sigrid Bülow2

1 Clinic and Polyclinic for Internal Medicine III, University Hospital Regensburg, Regensburg, Germany, 2 Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany, 3 Centre for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 4 Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany

The role of IL-22 in adult patients undergoing allogeneic stem cell transplantation (SCT) is of major interest since animal studies showed a protective and regenerative effect of IL-22 in graft versus host disease (GvHD). However, no clinical data exist on the tissue expression. Here we demonstrate that patients not suffering from transplant-related mortality (TRM) show significantly upregulated IL22 expression during histological and clinical GI-GvHD (p = 0.048 and p = 0.022, respectively). In contrast, in GvHD patients suffering from TRM, IL22 was significantly lower (p = 0.007). Accordingly, lower IL22 was associated with a higher probability of TRM in survival analysis (p = 0.005). In a multivariable competing risk Cox regression analysis, low IL22 was identified as an independent risk factor for TRM (p = 0.007, hazard ratio 2.72, 95% CI 1.32 to 5.61). The expression of IL22 seemed to be microbiota dependent as broad-spectrum antibiotics significantly diminished IL22 expression (p = 0.019). Furthermore, IL22 expression significantly correlated with G-protein coupled receptor (GPR)43 (r = 0.263, p = 0.015) and GPR41 expression (r = 0.284, p = 0.009). In conclusion, our findings reveal an essential role of IL-22 for the prognosis of patients undergoing allogeneic SCT.

Keywords: IL22, allogeneic SCT, GvHD, TRM, antibiotics, GPR41, GPR43
INTRODUCTION

Allogeneic hematopoietic stem cell transplantation (SCT) is a potentially curative therapy for patients with hematological disorders. Nevertheless, SCT is still associated with substantial mortality and morbidity with up to 50% of patients at the risk of developing acute graft versus host disease (GvHD) (1–3). Acute GvHD affects the skin, liver, and the gastro-intestinal (GI) tract (2). Severe GI-GvHD is associated with increased transplant-related mortality (TRM), reduced survival, and impaired quality of life (4). Within the GI-tract, epithelial cells are a sensitive target of GvHD. The gut epithelium is composed of enterocytes, Paneth cells, goblet cells, enteroendocrine cells, and tuft cells which are crucial players in tissue homeostasis (5). Thereby, the epithelial cell layer segregates gut microbiota from host immune cells and mediates signals between gut microbes and host immune cells (5). Protection and maintenance of gut epithelium remain crucial in the prevention and treatment of GI-GvHD.

IL-22 was first discovered in early 2000 and was described as IL-10 related T cell-derived inducible factor (6, 7). The human IL22 gene is located on chromosome 12q15, close to the IL26 and INFγ genes, and shares 80.8% sequence homology with murine IL-22 (8). In lymphoid tissue, αβ T cells, γδ T cells, innate lymphoid cells (ILCs), and natural killer T cells have been identified as cellular sources of IL-22 (9). In the context of GvHD, especially intestinal IL-22 produced by group 3 ILCs (ILC3s) has been shown to support intestinal epithelial regeneration and barrier function (10, 11). In murine models of acute GvHD, treatment with recombinant IL-22 increased the number of stem cells, improved epithelial integrity, enhanced the expression of antimicrobial peptides such as Reg3β and Reg3γ, and finally resulted in reduced mortality (11, 12). Furthermore, IL-22 has been shown to stimulate mucus production in a STAT3 dependent manner and goblet cell reconstitution within the mucosal epithelium leading to rapid attenuation of inflammation in a model of ulcerative colitis (13).
Concerning microbiota-induced IL-22 expression in murine models, Yang and colleagues showed that microbiota-derived short-chain fatty acids (SCFA) promoted IL-22 production by ILCs and T cells through G-protein coupled receptor 41 (GPR41) by inhibiting histone deacetylase (14). In addition, Chun et al. demonstrated that GPR43 regulates ILC3 expansion and IL-22 expression via AKT and STAT3 axis, thus supporting the role of microbiota in IL-22 expression (15).

Given the beneficial role of IL-22 in the context of inflammation, we sought to analyze the expression of IL22 in the gastrointestinal tract of SCT patients in the course of GvHD development. We found an association of high intestinal IL22 levels with low TRM after allogeneic SCT emphasizing a protective role of IL-22. Of importance, the use of broad-spectrum antibiotics strongly suppressed IL22 expression, and IL22 correlated with GPR41 and GPR43 expression. Our findings imply that enhancing expression or treatment with IL-22 has great potential to attenuate TRM after allogeneic SCT.

**MATERIALS AND METHODS**

**Patient Characteristics**

Biopsies of 118 patients receiving an allogeneic SCT at the University Hospital Regensburg, Germany, from 2008 to 2016 were included in the study. All patients gave informed consent for the GI-tract biopsies. Patient characteristics are given in Table 1. The study was approved by the local ethical review board of the University of Regensburg (approval numbers: 02/220, 09/059, and 17-619-101).

**Biopsy Characteristics**

Gastro-intestinal biopsies were obtained either in the course of screening study in asymptomatic patients (median 30 days, range 13 - 2,345 days), because of clinical symptoms indicative of de novo onset (median 51 days, range 14 - 479 days), or during persistence or recurrence of acute GI-GvHD (median 130 days, range 10 - 1,142 days).

**TABLE 1 | Summary of patient characteristics.**

| Characteristics | mean | (range) |
|----------------|------|---------|
| Age in years   | Patients (N = 118) | 53 | (20-69) |
|                | Sex | n (%) | |
|                | male | 66 | 55.9 |
|                | female | 52 | 44.1 |
| Diagnosis      | Acute leukemia | 67 | 56.8 |
|                | Myelodysplastic syndrome | 14 | 11.9 |
|                | Myeloproliferative syndrome | 7 | 5.9 |
|                | Lymphoma | 30 | 25.4 |
| Stage of underlying disease | Early | 34 | 28.8 |
|                | Intermediate | 44 | 37.3 |
|                | Advanced | 40 | 33.9 |
| Donor type     | Unrelated donor | 74 | 62.7 |
|                | Sibling | 38 | 32.2 |
|                | Haploidentical donor | 6 | 5.1 |
| Stem cell source | PBSC | 110 | 93.2 |
|                | BM | 8 | 6.8 |
| Conditioning regimen | Reduced intensity | 104 | 88.1 |
|                | Standard | 14 | 11.9 |
| Immunosuppression | CyA/MTX | 96 | 81.4 |
|                | CyA/MMF | 13 | 11.0 |
|                | Tacrolimus/MMF | 3 | 2.5 |
|                | PostTxCy/Tacro/MMF | 6 | 5.1 |
| Clinical GI-GvHD stage at time of biopsy | No GvHD | 60 | 50.8 |
|                | Stage 1 | 32 | 27.1 |
|                | Stage 2 | 11 | 9.3 |
|                | Stage 3 | 8 | 6.8 |
|                | Stage 4 | 7 | 5.9 |
| Lerner GI-GvHD stage at time of biopsy | No GvHD | 56 | 47.4 |
|                | Grade 1 | 36 | 30.5 |
|                | Grade 2 | 11 | 9.3 |
|                | Grade 3 | 9 | 7.6 |
|                | Grade 4 | 8 | 5.1 |

PBSC, peripheral blood stem cells; BM, bone marrow; CyA, cyclosporin; MTX, methotrexate; MMF, mycophenolate mofetil; Tacro, tacrolimus; PostTxCy, post-transplant cyclophosphamide.
range 37 - 538 days). Biopsies were histologically graded for the acute GI-GvHD according to the Lerner’s grading system (16). There were 56 patients who had no histological signs of acute GI-GvHD, 36 patients had GvHD grade 1, 11 patients had GvHD grade 2, 9 and 6 patients had GvHD grade 3 and 4, respectively.

RNA Extraction, cDNA Synthesis and qPCR
Following retrieval, biopsies were immediately transferred to 500 µl RNA protect (Qiagen) and were stored at - 80°C until RNA extraction. RNA extraction, including DNA digestion, was performed with RNeasy Mini Kit (Qiagen) as per the manufacturer’s instructions. RNA concentration and purity were monitored with NanoDrop and Bioanalyser, respectively. One microgram of RNA was transcribed to cDNA using moloney murine leukemia virus (MMLV) reverse transcriptase (Promega) according to the manufacturer’s instructions. qPCR was performed on a Mastercycler Ep Realplex (Eppendorf) for GPR43 and GPR41 and on HT 7900 Real-Time PCR system (Applied Biosystems) for IL22 using QuantFast SYBR Green PCR Kit (Qiagen). Genes of interest were normalized to the 18S rRNA reference gene.

Following gene-specific primer pairs were used:
IL22, forward: 5’-AGC-CCT-ATA-TCA-CCA-ACC-GC-3’,
reverse: 5’-TCT-CCC-CAT-GTA-GAC-GAA-CG-3’; GPR43, forward: 5’-GTA-GCT-AAC-ACA-AGT-CCA-GTC-CT-3’,
reverse: 5’-CTA-GGT-GTT-GCT-TTG-AAG-CTT-GT-3’; GPR41, forward: 5’-GCC-AAC-TGC-AGG-TCT-GGA-GAG-3’,
reverse: 5’-CTT-GCC-CAC-GAA-GAC-CAC-CA-3’; 18S rRNA, forward: 5’-ACC-GAT-ATG-ATG-GTT-TAG-TGA-G-3’, reverse: 5’-CCT-ACG-GAA-ACC-TTG-TTA-GGA-C-3’.

Immunofluorescence
Formalin-fixed paraffin embedded (FFPE) biopsies were cut approximately 3 µm thick and were immersed in xylene and descending alcohol line. Antigen retrieval was performed with citrate buffer (pH 7.2) at 350 watts for 32 minutes in a microwave. Subsequently, the biopsy was blocked with 20% bovine serum albumin (BSA) for 20 minutes, rinsed three times with PBS followed by incubation with anti-IL-22 (mouse monoclonal, clone 2D5, Merck Millipore) and anti-CD3 (rabbit monoclonal, clone SP7, Thermo Scientific) primary antibodies at 1:50 dilution in 1% BSA for 1 hour. Primary antibodies were labeled with Alexa Flour (AF) 488 (for IL-22) and AF594 (for CD3) and secondary antibodies for another hour. Nuclei were counterstained with DAPI. Images were taken with a Zeiss fluorescence microscope.

Statistical Analyses
Data were analyzed in SPSS version 26 (IBM) and R version 4.1.2 (The R Foundation for Statistical Computing). Test of normality was performed using Shapiro-Wilk test. Normally distributed data were analyzed with t-test or one way ANOVA. Non-normally-distributed data were analyzed with Mann-Whitney U test or Kruskal-Wallis test. Correlations were assessed by using Pearson or Spearman-rho correlation coefficient for normal and non-normally distributed data, respectively. Kaplan-Meier method was used to calculate the probability of TRM. To analyze the impact of IL22 on TRM, uni- and multivariable competing risk Cox regression models were used accounting for relapse related mortality as competing risk event. Time to day of biopsy to day of death or to last day of patient being confirmed to be alive (censored cases). The multivariable model was adjusted for the additional covariates GI-GvHD, age, steroids, stage of disease, donor type, broad spectrum antibiotics and conditioning. Since biopsies were taken at different time points after SCT, we also added time from SCT to biopsy as potential confounder to the model. Hazard Ratios (HR) and corresponding 95%-confidence intervals (95%-CI) are reported as effect estimates. All competing Cox regression analyses were evaluated using the CurrIncidence function (17) and the factor2ind function (18) of the cmprsk_2.2-11 package in R version 4.1.2. Multivariable competing risk regression analyses was done in 110 of 118 patients since data on antibiotics at the time of biopsy were missing on 8 patients. A p-value < 0.05 was considered statistically significant for all analyses. Data were depicted using Graph Pad Prism, version 7.00 (GraphPad Software).

RESULTS
IL22 Is Upregulated in Patients Surviving GvHD
First, we were interested in whether GvHD patients show distinct IL22 mRNA expression compared to patients who did not develop acute GI-GvHD. When we classified patients according to Lerner grades, IL22 expression did not significantly differ between patients without GvHD or with mild to severe GvHD (Supplementary Figure 1A). When comparing screening biopsies of patients without clinical GI-GvHD to those derived at clinical onset, significant upregulation of IL22 was found in the latter (p = 0.043, Supplementary Figure 1B). Since IL-22 administration has a positive impact on survival in murine GvHD (11, 12), we tested the hypothesis that IL22 expression might have an impact on transplant-related mortality (TRM) and therefore separated the patients in regard to both, GvHD and TRM. In our cohort, patients experiencing TRM died mainly of infection, GvHD, or toxicity. The precise cause of death is listed in Table 2. Most importantly, within the patient group suffering from acute, histologically proven GI-GvHD, those with TRM showed significantly lower IL22 mRNA expression compared to those without TRM (p = 0.007, Figure 1A). Similarly, clinically defined onset patients tended to show lower IL22 expression in the TRM group as compared to the non-TRM group (p = 0.060, Figure 1B). Interestingly, in the patient group without TRM, histological GvHD was associated with a significantly higher IL22 expression compared to patients without histological GvHD (p = 0.048, Figure 1A). From a clinical perspective, in the patient group without TRM, IL22 expression was pronounced at the onset of GvHD compared to screening biopsies (p = 0.022, Figure 1B). In conclusion, IL22 is significantly upregulated in GvHD patients not dying from TRM.

Ghimire et al. Intestinal IL22 After Allogeneic SCT

Frontiers in Immunology | www.frontiersin.org April 2022 | Volume 13 | Article 857400
IL22 Expression Is Low in Patients With Subsequent TRM

When we examined the impact of IL22 on prognosis after allogeneic SCT, including patients with and without GvHD, we observed significantly lower IL22 expression in the TRM group compared to the non-TRM group ($p = 0.010$, Figure 2A). To further address this association, we dichotomized patients into high and low expression of IL22 based on ROC curve analysis and a Youden index of 0.6435. Kaplan-Meier analysis revealed a significantly higher probability of TRM in patients with low IL22 expression ($p = 0.004$, Supplementary Figure 2). In addition to the 36 patients dying by TRM, 31 patients died of relapse (relapse related mortality, RRM) as a competing event. Moreover, observation times, as measured from biopsy retrieval until the occurrence of the event (such as TRM or relapse) or the last follow up, varied. Therefore, a time-dependent competing risk analysis was performed revealing a significant association of low IL22 with the probability of TRM ($p = 0.005$, Figure 2B). In contrast, no significant association of IL22 and RRM was observed ($p = 0.334$, Figure 2B). Time-dependent Cox regression analysis revealed low IL22 ($p = 0.007$, hazard ratio 2.72, 95% CI 1.32 to 5.61) and acute GI-GvHD ($p = 0.010$, hazard ratio 3.12, 95% CI...
1.32 to 7.39) as independent risk factors for TRM (Table 3). Established risk factors such as age, steroids, stage of disease, donor type, broad spectrum antibiotics or conditioning were not significantly associated. Furthermore, no influence of the time between the recent transplantation and biopsy retrieval was found. In summary, low expression of IL22 in intestinal biopsies associates with an increase in transplant-related mortality after allogeneic stem cell transplantation.

**Broad-Spectrum Antibiotics Suppresses IL22 Expression**

The application of broad-spectrum antibiotics (Abx) within 7 days before obtaining biopsies was used as an indirect indicator of microbiota damage (19) with 60% of patients receiving carbapenems (meropenem), 35% of patients receiving piperacillin/tazobactam and only 5% of patients receiving cephalosporins (ceftazidim). Since the lower GI-tract harbors the majority of microbiota (20), we analyzed IL22 status in lower GI-tract (n = 86) with respect to use of Abx treatment and observed a significant lower IL22 mRNA in patients receiving Abx compared to patients not treated with Abx (p = 0.019, Figure 3). When we included upper GI tract biopsies in our analyses, we still observed marked suppression of IL22 in antibiotic group with a trend towards significance (no Abx: median = 1.88, range = 0 - 898; Abx: median = 1.21, range = 0 - 85.8, p = 0.085). In conclusion, reduction of commensals as

| TABLE 3 | Multivariable Cox regression analysis for TRM. |
|----------|------------------|------------------|------------------|
| Risk factors | P value | HR | 95% CI for HR |
| Low IL22 (n = 41) | 0.007 | 2.72 | 1.32 – 5.61 |
| Grade 2-4 GI-GvHD (n = 25) | 0.010 | 3.12 | 1.32 – 7.39 |
| Patient’s age (> 50 years, n = 75) | 0.140 | 1.93 | 0.80 – 4.66 |
| Steroid (n = 59) | 0.170 | 1.81 | 0.77 – 4.26 |
| Broad spectrum antibiotics (n = 48) | 0.340 | 1.40 | 0.71 – 2.78 |
| Conditioning (Standard, n = 13) | 0.470 | 1.41 | 0.55 – 3.61 |
| Donor (MUD, n = 68) | 0.750 | 0.88 | 0.42 – 1.88 |
| Stage of underlying disease (advanced, n = 37) | 0.750 | 1.13 | 0.53 – 2.40 |
| Time of recent SCT to biopsy | 0.970 | 1.00 | 1.00 – 1.00 |

A total of 110 patients were analyzed. High-risk groups with respective numbers are indicated for categorical variables. HR, hazard ratio; CI, confidence interval; MUD, matched unrelated donor.

**FIGURE 3 | Impact of broad-spectrum antibiotics on IL22 expression.** IL22 expression in biopsies derived from the lower GI tract of patients after allogeneic SCT is depicted (no Abx: n = 50, Abx: n = 36). Box plot diagram depicts median, upper, and lower quartiles and whiskers indicate minimal and maximal values. Negative values were set to 0.1. Statistical testing was performed using Mann-Whitney U test.
implicated by the use of Abx negatively affected IL22 expression in the lower GI in our cohort.

**IL22 Correlates With GPR41 and GPR43 Expression**

To identify IL-22 cellular source in patient biopsies, we performed immunofluorescent staining using IL-22- and CD3-specific antibodies in sigmoid colon biopsies (Supplementary Figure 3). IL-22+ cells were detected both within CD3+ and CD3 cells. Microbiota-derived SCFA were shown to increase IL-22 expression in CD3+ ILC3 via GPR43 and both CD3+ ILCs and CD3+ T cells via GPR41 in murine models (14, 15). To further explore the role of microbiota on IL22 expression in allogeneic SCT patients, we examined the association of IL22 with SCFA receptors GPR43 and GPR41 in the intestinal biopsies of the lower GI tract (Figure 4). Indeed, a significant positive correlation between IL22 and GPRs was observed.

**DISCUSSION**

The central goal of this study was to investigate the role of IL22 in the context of allogeneic SCT with focus on GI-GvHD. Here, we show for the first time a significant reduction of IL22 in the intestinal biopsies of patients who experienced TRM emphasizing the importance of IL22 in the context of stem cell transplantation. Especially increased expression of IL22 in non-lethal compared to lethal GI-GvHD implicates IL22 as a major survival factor in patients suffering from GvHD. In this context, the upregulation of IL22 appears to compensate or counter-regulate ongoing inflammation as already seen for Foxp3 (21), IDO (22) and GPR (23) in gastric or colonic biopsies of GvHD patients. A previous study by Lounder and colleagues analyzed serum IL-22 in pediatric SCT patients and showed an association with higher serum IL-22 with subsequent GI-GvHD but not with the incidence of TRM (24). In contrast, we found a significant reduction of intestinal IL22 in patients with subsequent TRM. Thereby, differences between a pediatric and adult cohort might exist. Moreover, intestinal IL22 mRNA measured in our study might not inevitably reflect IL-22 protein and, additionally, IL-22 levels in the gut and in the serum do not necessarily have to correlate. In this context, data exist on Reg3α where high Reg3α levels in the serum paradoxically reflected the lack of Reg3α-positive Paneth cells in the gut mucosa (25, 26).

The observation that low intestinal IL22 expression is associated with a higher rate of TRM implicates the potential role of IL-22-mediated epithelial regeneration that has previously been described in the murine model of GvHD (10). In line with these data, the multivariable Cox regression model revealed low IL22 levels as a possible risk factor for TRM, which, interestingly, was independent of the presence of GvHD at the time of biopsy. The association of IL22 with cumulative incidence of TRM in a competing risk analysis makes IL-22 an attractive tool for therapy in transplantation. In fact, the administration of recombinant IL-22 in a murine GvHD model strongly decreased gut GvHD pathology (27). In a recent phase II clinical trial, the use of IL-22 (in combination with standard immunosuppressants) for the treatment of acute GvHD showed a positive response rate of 100%, 75%, and 58% in a low-, intermediate-, and high-risk biomarker constellations, respectively (28), providing a proof-of-concept for the efficacy of IL-22 therapy. It may be hypothesized that IL-22 plays important role in the recovery from treatment-associated tissue and stem cell damage and, thus, increases tissue tolerance and enhances survival.

One remarkable finding of our work is the influence of Abx on IL22 expression in intestinal biopsies. Owing to the detrimental effect of Abx on microbial diversity (19, 29, 30), butyrate-producing bacteria (31) and the receptors of microbial metabolite such as GPR109a and GPR43 (23), our data hints towards the necessity of balanced microbiota, metabolites, and receptors for optimal IL22 production in GvHD patients. In analogy to data in mice (15), Abx treatment in patients with loss of commensals could lead to a reduction of protective metabolites followed by downregulation of SCFA receptors and, hence, reduced IL22. Besides T cells, ILCs are the main producer of IL-22 during inflammation (32). ILCs are known to express GPR43 to a higher extent when compared to

![FIGURE 4](image_url) | Correlation between IL22 and GPRs. Correlation of IL22 with (A) GPR43 (n = 86) and (B) GPR41 (n = 84) in biopsies derived from the lower GI tract is depicted. Negative values for IL22 were set to 0.1, for GPR43 to 0.00005 and for GPR41 to 0.001. Statistical testing was performed using Spearman’s correlation.
macrophages, dendritic cells, or NK cells in the murine colon (15). In line with this observation, we found a significant positive correlation between IL-22 and GPR43 in the intestinal biopsies of patients. Additionally, IL-22 also correlated significantly with GPR41 which was shown to promote SCFA-mediated IL-22 production (14). Thus, our data suggest that the protective role of IL-22 is a possible explanation for the impact of microbiota on outcome after allogeneic SCT. Although the decrease of IL-22 in the course of Abx use and correlation of IL-22 with GPRs strengthen this hypothesis, a limitation of our study is the lack of data on the microbiome status at the time of biopsy retrieval. Therefore, the relation between IL-22 expression and microbiota status will be addressed in future studies.

In conclusion, our analysis of intestinal biopsies from allogeneic SCT patients further highlights the outstanding importance of IL-22 on the clinical outcome after allogeneic SCT and strengthens the therapeutic potential of IL-22 for the amelioration of GvHD associated complications.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Aktive Ethikvoten der Ethik-Kommission der Universität Regensburg Email: ethikkomission@ur.de. The patients/participants provided their written informed consent to participate in this study (approval no: 02/220, 09/059, 17-619-101). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
SG performed experiments, collected and analyzed data, and wrote the manuscript. KE performed experiments, collected data, and revised the manuscript. EM and DWe collected clinical data and revised the manuscript. CM, AH, FZ, DWo, ME, HP, WH, AG, EH discussed and revised the manuscript. SB supervised the project, analyzed data, and wrote the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-Versus-Host Disease. Lancet (2009) 373(9674):1550–61. doi: 10.1016/S0140-6736(09)60237-3
2. Ghimire S, Weber D, Mavin E, Wang XN, Dickinson AM, Holler E. Pathophysiology of GvHD and Other HSCT-Related Major Complications. Front Immunol (2017) 8:799. doi: 10.3389/fimmu.2017.00799
3. Zeiser R, Blazar BR. Acute Graft-Versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med (2017) 377(22):2167–79. doi: 10.1056/NEJMra1609337
4. Pasquini MC. Impact of Graft-Versus-Host Disease on Survival. Best Pract Res Clin Haematol (2008) 21(2):193–204. doi: 10.1016/j.beha.2008.02.011
5. Okumura R, Takada K. Roles of Intestinal Epithelial Cells in the Maintenance of Gut Homeostasis. Exp Mol Med (2017) 49(5):e338. doi: 10.1038/emm.2017.20
6. Dumoutier L, Louahed J, Renaud JC. Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), A Novel Cytokine Structurally Related to IL-10 and Inducible by IL-9. J Immunol (2000) 164(4):1814–9. doi: 10.4049/jimmunol.164.4.1814
7. Dumoutier L, Van Roost E, Colau D, Renaud JC. Human Interleukin-10-Related T Cell-Derived Inducible Factor: Molecular Cloning and Functional

FUNDING
This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -Projektnummer 324392634 - TRR 221”, Wilhelm Sander Foundation, Grant 2017.020.1 “Dysbiosis and intestinal immunoregulation in GvHD”, Marie Curie Initial Training Networks, Project Number 315963, the Else-Kroener-Fresenius-Stiftung, the Bavarian Ministry of Science and the Arts in the framework of the Bavarian Research Network “New Strategies Against Multi-Resistant Pathogens by Means of Digital Net-working – bayresq.net and CRC 1371, DFG “Microbiome signatures”.

ACKNOWLEDGMENTS
We acknowledge our technicians Heike Bremm, Massimiliano Caioni, Nicole Ritter, Tatjana Schifferstein and Yvonne Schumann for the technical support.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.857400/full#supplementary-material

Supplementary Figure 1 | IL22 expression in dependence of GvHD IL22 gene expression normalized to 18s rRNA was measured. (A) Patients were grouped according to histological Gv-GvHD using Lerner’s grading system (no GvHD: n = 56, GvHD 1: n = 36, GvHD 2: n = 11, GvHD 3-4: n = 15). (B) Expression of IL22 in patients during clinical GvHD (screen: n = 65, onset: n = 40, ongoing: n = 13). Box plot diagrams depict median, upper, and lower quartiles and whiskers indicate minimal and maximal values. Negative values were set to 0.1. Statistical testing was performed by Mann-Whitney U test. ns, not significant.

Supplementary Figure 2 | Association of IL22 with probability of TRM. Patients were dichotomized in accordance to high (red line) and low expression (blue line) of IL22 based on Youden index. The probability of TRM in dependence of the months after biopsy is shown.

Supplementary Figure 3 | Immunofluorescence staining of IL-22 and CD3 in the sigmoid colon biopsies of GvHD patients after allogeneic SCT. One of four representative biopsies derived from four independent patients is shown. The exemplified biopsy was taken on day 303 after SCT. The patient was not under steroids or Abx at the time of biopsy. IL-22 corresponds to AF488 (green) while CD3 corresponds to AF594 (red). Nuclei is counterstained with DAPI (blue signals). Image in the upper panel is taken at a 10x magnification. Lower panels represent magnified sections where white arrows represent CD3+IL-22+ cells and yellow arrows represent CD3+IL22+ cells. Scale bar, upper panel: 200 µm, lower panels: 50 µm.
Characterization as an Hepatocyte-Stimulating Factor. Proc Natl Acad Sci USA (2000) 97(18):10144–9. doi: 10.1073/pnas.170291697.

8. Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: Two Novel Cytokines With Importance in Inflammatory Diseases. Expert Opin Ther Targets (2007) 11(5):601–12. doi: 10.1517/14728228.11.5.601

9. Parks OB, Pociask DA, Hodzic Z, Kolls JK, Good M. Interleukin-22 Signaling in the Regulation of Intestinal Health and Disease. Front Cell Dev Biol (2015) 3:85. doi: 10.3389/fcell.2015.00085

10. Hanash AM, Dudakov JA, Young LF, Singer NV, et al. Interleukin-22 Protects Intestinal Stem Cells From Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft Versus Host Disease. Immunity (2012) 37(2):339–50. doi: 10.1016/j.immuni.2012.05.028

11. Lindemans CA, Calafiore M, Mertelsmann AM, O'Connor MH, Dudakov JA, Jenq RR, et al. Interleukin-22 Promotes Intestinal Stem-Cell-Mediated Epithelial Regeneration. Nature (2015) 528(7583):560–4. doi: 10.1038/nature16460

12. Zhao D, Kim YH, Jeong S, Greenson JK, Chaudhry MS, Hoeffling P, et al. Survival Signal REG3γ Prevents Crypt Apoptosis to Control Acute Gastrointestinal Graft-Versus-Host Disease. J Clin Invest (2018) 128(11):4970–9. doi: 10.1172/JCI99261

13. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 Ameliorates Intestinal Inflammation in a Mouse Model of Ulcerative Colitis. J Clin Invest (2008) 118(2):534–44. doi: 10.1172/JCI33194

14. Yang W, Yu T, Huang X, Bilotta AJ, Xu L, Lu Y, et al. Intestinal Microbiota-Derived Short-Chain Fatty Acids Regulation of Immune Cell IL-22 Production and Gut Immunity. Nat Commun (2020) 11(1):1–18. doi: 10.1038/s41467-020-18262-6

15. Chun E, Lavoie S, Fonseca-Pereira D, Bae S, Michaud M, Hoveyda HR, et al. Metabolite-Sensing Receptor Ffr2 Regulates Colonic Group 3 Innate Lymphoid Cells and Gut Immunity. Immunity (2019) 51(5):871–84.e6. doi: 10.1016/j.immuni.2019.09.014

16. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of Graft-vs.-Host Reaction (GvHR) in Human Recipients of Marrow From HL-A-Matched Sibling Donors. Transplant Proc (1974) 6(4):367–71.

17. Scrucca L, Santucci A, Aversa F. Competing Risk Analysis Using R: An Easy Guide for Clinicians. Bone Marrow Transplant (2007) 40(4):381–7. doi: 10.1038/sj.bmt.2507727

18. Scrucca L, Santucci A, Aversa F. Regression Modeling of Competing Risk Using R: An in Depth Guide for Clinicians. Bone Marrow Transplant (2010) 45(9):1388–95. doi: 10.1038/bmt.2009.359

19. Weber D, Jenq RR, Peled IU, Taur Y, Hiergeist A, Koestler J, et al. Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome After Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant (2017) 23(5):845–52. doi: 10.1016/j.bbmt.2017.02.006

20.Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PloS Biol (2016) 14(8):e1002533. doi: 10.1371/journal.pbio.1002533

21. Lord JD, Hackman RC, Gooley TA, Wood BL, Moklebust AC, Hockenbery DM, et al. Blood and Gastric FOXP3+ T Cells Are Not Decreased in Human Gastric Graft-Versus-Host Disease. Biol Blood Marrow Transplant (2011) 17(4):486–96. doi: 10.1016/j.bbmt.2010.09.015

22. Landfried K, Zhu W, Waldhier MC, Schulz U, Ammer J, Holler B, et al. Tryptophan Catabolism Is Associated With Acute GVHD After Hematopoietic Stem Cell Transplantation and Indicates Activation of Indoleamine 2,3-Dioxygenase. Blood (2011) 118(26):6971–4. doi: 10.1182/blood-2011-06-357814

23. Ghimire S, Weber D, Hippe K, Meedt E, Hoeffling P, Kattner AS, et al. GPR Expression in Intestinal Biopsies From SCT Patients Is Upregulated in GvHD and Is Suppressed by Broad-Spectrum Antibiotics. Front Immunol (2021) 12:753287. doi: 10.3389/fimmu.2021.753287

24. Louwander DT, Khandelwal P, Gloude NJ, Dandoy CE, Jodke S, Medvedov M, et al. Interleukin-22 Levels Are Increased in Gastrointestinal Graft-Versus-Host Disease in Children. haematologica (2018) 103(10):e480. doi: 10.3324/haematol.2017.174771

25. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, et al. Plasma Biomarkers of Lower Gastrointestinal and Liver Acute GVHD. Blood J Am Soc Hematol (2012) 119(12):2960–3. doi: 10.1182/blood-2011-10-387357

26. Levine JE, Huber E, Hammer ST, Harris AC, Greenson JK, Braun TM, et al. Low Paneth Cell Numbers at Onset of Gastrointestinal Graft-Versus-Host Disease Identify Patients at High Risk for Nonrelapse Mortality. Blood J Am Soc Hematol (2013) 122(8):1505–9. doi: 10.1182/blood-2013-02-485813

27. Mertelsmann AM, Dudakov JA, Velardi E, Hua G, Kreines FM, Levy ER, et al. IL-22 Administration Decreases Intestinal GVHD Pathology, Increases Intestinal Stem Cell Recovery, and Enhances Immune Reconstitution Following Allogeneic Hematopoietic Transplantation. Am Soc Hematol Washington DC (2013) 122:290. doi: 10.1182/blood.v122.21.290.290

28. Ponce DM, Alousi AM, nakamura R, Sandhu KS, Barker JN, Shia J, et al. A Phase 2 Study of F-652, a Novel Tissue-Targeted Reconstituant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute GVHD of the Lower GI Tract. Biol Blood Marrow Transplant (2020) 26(3):551–52. doi: 10.1016/j.bbmt.2019.12.124

29. Weber D, Hiergeist A, Weber M, Dettmer K, Wolfl D, Hahn J, et al. Detrimental Effect of Broad-Spectrum Antibiotics on Intestinal Microbiome Diversity in Patients After Allogeneic Stem Cell Transplantation: Lack of Commensal Sparing Antibiotics. Clin Infect Dis (2019) 68(8):1303–10. doi: 10.1093/cid/ciy711

30. Weber D, Oefner PJ, Hiergeist A, Koestler J, Gessner J, Weber M, et al. Low Urinary Indoxyl Sulfate Levels Early After Transplantation Reflect a Disrupted Microbiome and are Associated With Poor Outcome. Blood (2015) 126(14):1723–8. doi: 10.1182/blood-2015-04-688858

31. Meedt E, Hiergeist A, Gessner J, Dettmer K, Liebsch G, Ghimire S, et al. Prolonged Suppression of Butyrate-Producing Bacteria Is Associated With Acute Gastrointestinal Graft-Vs-Host Disease and Transplantation-Related Mortality After Allogeneic Stem Cell Transplantation. Clin Infect Dis (2021) 74(4):614–21. doi: 10.1093/cid/ciaa500

32. Rutz S, Eidenschenk C, Ouyang W. IL-22, Not Simply A Th17 Cytokine. Immunol Rev (2015) 252(1):116–32. doi: 10.1111/imr.12027

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ghimire, Ederer, Meedt, Weber, Matos, Hiergeist, Zeman, Wolff, Edinger, Poeck, Herr, Gessner, Holler and Bälow. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.